Daratumumab-VCd Improves Survival, Organ Function in AL Amyloidosis

Advancing Treatment for Light-Chain Amyloidosis

Systemic immunoglobulin light-chain (AL) amyloidosis is a rare plasma cell disorder driven by the extracellular deposition of misfolded monoclonal light chains, which form insoluble amyloid fibrils in tissues and organs [1, 2]. This process leads to progressive organ dysfunction, with cardiac involvement being a primary determinant of prognosis and a major cause of death [3, 4, 5]. Consequently, treatment strategies aim to rapidly eradicate the underlying plasma cell clone to halt the production of these toxic light chains, thereby enabling organ recovery and improving survival [1, 2]. While regimens combining bortezomib, cyclophosphamide, and dexamethasone (VCd) have been a standard, the addition of daratumumab, a monoclonal antibody targeting the CD38 protein on plasma cells, has shown significant activity [1, 6, 5]. The final, long-term survival data from a pivotal trial now confirm the substantial clinical benefit of this combination.

ANDROMEDA Trial Design and Primary Endpoint

This report presents the preplanned final analysis of the ANDROMEDA trial, a phase 3, randomized study that provided the basis for the approval of daratumumab in this setting. The trial enrolled 388 patients with newly diagnosed AL amyloidosis and assigned them to one of two arms. The control group received six cycles of the standard VCd regimen alone. The investigational arm received the same six cycles of VCd with the addition of subcutaneous daratumumab (D-VCd), followed by maintenance therapy with single-agent subcutaneous daratumumab every four weeks for up to 24 total cycles. The primary endpoint was the rate of hematologic complete response (CR), a measure of how effectively the underlying plasma cell clone is suppressed. Initial results from the trial had already demonstrated the superiority of the D-VCd regimen, establishing it as the only therapy specifically approved for AL amyloidosis. This final analysis, registered on ClinicalTrials.gov as NCT03201965, provides a comprehensive look at long-term outcomes.

Deeper and Faster Hematologic Responses

The final analysis confirmed and strengthened the initial findings regarding hematologic response. The addition of daratumumab to VCd resulted in a more than threefold increase in the rate of hematologic complete response, with an updated CR rate of 59.5% in the D-VCd group compared to just 19.2% in the VCd group. This difference was highly statistically significant, yielding an odds ratio of 6.03 (95% confidence interval [CI], 3.80-9.58; P<0.0001). For clinicians, this profound suppression of the pathogenic plasma cells is the first critical step toward halting organ damage. Furthermore, the D-VCd regimen achieved these deep responses more quickly. The median time to hematologic CR was 67.5 days (range, 8.0-879.0) with D-VCd, compared to 85.0 days (range, 14.0-617.0) with VCd alone. This accelerated response is clinically vital, as it shortens the duration of ongoing amyloid fibril production and deposition in vulnerable organs.

Sustained Organ Function and Survival Benefits

With a mature median follow-up of 61.4 months, the superior hematologic responses translated directly into durable clinical benefits. The D-VCd regimen demonstrated a substantial improvement in major organ deterioration-progression-free survival (MOD-PFS), a key composite endpoint measuring the time to worsening of vital organ function, disease progression, or death. The risk of one of these events was reduced by more than half, with a hazard ratio of 0.44 (95% CI, 0.31-0.63; P<0.0001). This survival advantage was also evident in overall survival, where the D-VCd arm showed a statistically significant reduction in the risk of death, with a hazard ratio of 0.62 (95% CI, 0.42-0.90; P=0.0121). These long-term outcomes were supported by superior organ recovery; cardiac and renal response rates were two to three times higher in patients receiving D-VCd compared to those receiving VCd alone. The findings show a clear link between deeper hematologic suppression and the preservation of organ function, ultimately leading to longer survival.

Clinical Implications and Safety Profile

The long-term data from ANDROMEDA reinforce a central principle in the management of AL amyloidosis: the depth and quality of response are powerful prognostic indicators. The analysis confirmed that achieving either a hematologic or a cardiac complete response was strongly associated with improved major organ deterioration-progression-free survival and overall survival. This validates these early treatment milestones as critical goals for therapy, underscoring the value of a regimen like D-VCd that can achieve them in a majority of patients. From a safety perspective, the study was reassuring. The researchers reported that adverse events were consistent with the well-established safety profiles of both the VCd regimen and single-agent daratumumab. No new or unexpected toxicities emerged from the combination, which is an important consideration for clinicians managing this fragile patient population. By delivering deep, rapid, and durable responses that translate into organ recovery and a significant survival benefit, all with a predictable safety profile, the D-VCd regimen is solidified as a standard of care for newly diagnosed AL amyloidosis.

References

1. Roussel M, Kastritis E, Schönland S, et al. TeclistAMY (EMN40): A Phase 2 trial of teclistamab in patients with previously treated light-chain (AL) amyloidosis. Blood. 2025. doi:10.1182/blood-2025-3974

2. Sanchorawala V. Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis. HemaSphere. 2022. doi:10.1097/hs9.0000000000000681

3. Rahman M, Khan A, Ijaz A, et al. Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review. Blood. 2018. doi:10.1182/blood-2018-99-115214

4. Minnema MC, Dispenzieri A, Merlini G, et al. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.. JACC. CardioOncology. 2022. doi:10.1016/j.jaccao.2022.08.011

5. Aimo A, Vergaro G, Castiglione V, et al. [Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC)].. Giornale italiano di cardiologia (2006). 2026. doi:10.1714/4636.46471

6. Mammadzadeh A, Nagaraj M, Sra M, et al. Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA). Blood. 2024. doi:10.1182/blood-2024-208457